Umoja Biopharma
25 articles with Umoja Biopharma
-
Umoja Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Umoja Biopharma, Inc. announced that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023 in San Francisco, CA.
-
Umoja Biopharma Appoints Dieter Weinand as the Chair of its Board of Directors
12/14/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, announced the appointment of Dieter Weinand to its Board of Directors where he will take on the role of Chair, effective November 17, 2022.
-
Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies
11/21/2022
Umoja Biopharma, Inc. and IASO Biotherapeutics announced today that they have entered into a research agreement to evaluate Umoja's iCIL platform with IASO's best-in-class CARs,
-
Umoja Biopharma Presents New Preclinical Data on its Integrated In Vivo CAR T and Engineered Induced Pluripotent Stem Cell Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
11/10/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, announced today new data from three poster presentations at the 2022 Society for Immunotherapy of Cancer 37th Annual Meeting.
-
BioSpace checked in with some of the members of our NextGen Bio Class of 2022 to see what they've done to earn their place on the list - and what's on the horizon.
-
Umoja Biopharma to Present Three Posters Data on its Integrated In Vivo CAR T and ShRED Platform Technologies at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
10/19/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that it will have three poster presentations at the 2022 Society for Immunotherapy for Cancer 37th Annual Meeting.
-
Umoja Biopharma Appoints Igor I. Slukvin, M.D., Ph.D. to its Scientific Advisory Board
9/13/2022
Umoja Biopharma, Inc. announced the appointment of Igor I. Slukvin, M.D., Ph.D. to its Scientific Advisory Board.
-
Umoja CEO Andy Scharenberg spoke with BioSpace about the company's unique tri-platform approach to immunotherapy which aims to attack and destroy hematologic and solid organ-based tumors.
-
The BioForest region is growing up. With a focus on cell and gene therapy, a wealth of talent and proximity to high tech, it is quickly becoming one of biotech's most exciting hotbeds.
-
Umoja Biopharma Presents New Preclinical Data at the 2022 iPSC Manufacturing Summit on Synthetic Receptor Enabled Differentiation
7/28/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced new data at the 2022 iPSC Manufacturing Summit held in Boston, Mass.
-
Umoja Biopharma Announces Participation in Upcoming Scientific Summits
6/30/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that the company will participate in two Hanson Wade summits taking place in July in Boston.
-
Umoja Biopharma Presents Data on its Engineered Induced Pluripotent Stem Cell Platform at the 2022 International Society for Stem Cell Research Annual Meeting
6/16/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced today that it will have a poster presentation at the 2022 International Society for Stem Cell Research (ISSCR) Annual Meeting, to be held June 15-18, 2022 in San Francisco, California.
-
Umoja Biopharma and Lupagen Announce New Collaboration to Improve Patient Experience and Access to Next-Generation In Vivo Therapeutics for Cancer
5/23/2022
Umoja Biopharma, Inc. and Lupagen, Inc. announced they have entered into a collaboration to evaluate extracorporeal in vivo delivery as a potential additional route of administration for Umoja’s VivoVec particles using Lupagen’s Side CAR-T™ technology.
-
Umoja Biopharma Presents New Preclinical Data at ASGCT 2022 Annual Meeting on its VivoVec Platform Describing Preclinical Safety Data for UB-VV100 Product Candidate
5/19/2022
Umoja Biopharma, Inc. announced data from three presentations at the American Society of Gene and Cell Therapy Annual Meeting on its scalable, off-the-shelf in vivo lentiviral vector-based platform, termed VivoVec, that has the potential to achieve efficient T cell transduction upon direct administration to patients.
-
Umoja Biopharma Announces Resignation of Board Chair Clay B. Siegall
5/11/2022
Umoja Biopharma, Inc. announced Clay B. Siegall, Ph.D. agreed to the Company’s request to resign from Umoja’s board of directors, effective immediately.
-
Umoja Biopharma Presents Data on its Synthetic Cytokine Receptor Platform at the International Society for Cell and Gene Therapy Annual Meeting 2022
5/4/2022
Umoja Biopharma, Inc. announced that it will have an oral presentation at the International Society for Cell and Gene Therapy Annual Meeting 2022, to be held May 4-7, 2022 in San Francisco, California.
-
Umoja Biopharma Announces Activation of First ENLIGHTen Phase 1 Trial Site in Study of UB-TT170.
5/3/2022
Umoja Biopharma, Inc. announced today the Seattle Children’s activation of the Phase 1 ENLIGHTen clinical trial in patients with osteosarcoma to assess the safety and tolerability of autologous “universal” CAR T cells when administered with UB-TT170.
-
Umoja Biopharma to Present at the American Society of Gene and Cell Therapy 25th Annual Meeting
5/2/2022
Umoja Biopharma, Inc. announced that it will have an oral presentation and two posters at the American Society of Gene and Cell Therapy 25th Annual Meeting, to be held May 16-19, 2022.
-
Successful biotech companies have a certain way of thinking that propels everyone working there beyond day-to-day concerns and enables them to do great things. BioSpace highlights nine commonalities.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.